NOV 01, 2016 12:45 PM PDT

New Drug Targets for Atherosclerosis Limit Macrophage Activation

WRITTEN BY: Kara Marker
Two interactive proteins were discovered in connection to atherosclerosis-related macrophage activation, according to a new study from scientists at Brigham and Women’s Hospital. Researchers are interested in understanding how the proteins enhance or inhibit macrophage activation in order to better treat atherosclerosis and other arterial diseases.  
Immunofluorescence staining for PARP9 (red) and PARP14 (green) with nuclei shown in blue.
Macrophage activation and arterial disease go hand in hand, or so it seems. In his 2005 study on macrophage activation, atherosclerosis, and the pathogenesis of plaque rupture, author Joseph Boyle explain that “macrophages are innate immune effectors, i.e. they are activated without antigenic specificity. This may make them liable to indiscriminate tissue damage, since they are less selective than lymphocytes.” While macrophages are key players in the immune system that target foreign particles, they are also abundantly found in ruptured atherosclerotic plaques, indicated a “dark side” that needs to be addressed.

"Macrophage activation plays a role in not only vascular disorders but also various inflammatory and autoimmune diseases," said Masanori Aikawa, MD, PhD from the new study published in Nature Communications. "These results could provide important information about the mechanisms of these diseases and help to develop much needed new therapeutics."

Aikawa’s study started with a global proteomic analysis of macrophage cell lines to identify the proteins responsible for macrophage activation. Researchers identified PARP9 and PARP14, proteins from the same family found to regulate macrophage activation. The proteins were further linked to arterial disease causation through proteomic screening.

Researchers then silenced individually each gene that coded for PARP9 and PARP14 respectively in cultured macrophages, and the resulting effect seemed to be equal and opposite.

Inhibiting the activation of PARP14 through gene silencing increased macrophage activation, triggered activation of pro-inflammatory genes, and suppressed the expression of anti-inflammatory genes. On the other hand, inhibting activation of PARP9 decreased macrophage activation and suppressed pro-inflammatory genes.

With further study, researchers connected a deficiency in PARP14 in haematopoietic cells to an acceleration in the development and “inflammatory burden” of acute and chronic atherosclerotic lesions in mice. PARP9 worked to promote interferon-induced responses in macrophages, while PARP14 suppressed these responses. Overall, the two proteins appeared to have clear physical and functional interactions.

With a clearer understanding of the genetic influences behind atherosclerosis-related macrophage activation, Aikawa and the team plan to apply their findings to the drug development process, hoping to cut down the overall process length by making each individual step more efficient.

Drugs like statins exist to reduce cholesterol in effort to prevent atherosclerosis development, but scientists are seeing the global burden of ischemic heart disease only increase. With two proteins clearly implicated in the world of macrophage activation, scientists can start on new therapies that target and influence them.  
 


Sources: Current Vascular Pharmacology, Brigham and Women’s Hospital
Image: Masanori Aikawa, Brigham and Women's Hospital
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JAN 06, 2020
Cardiology
JAN 06, 2020
Online Therapy Treats Depression in Heart Disease Patients
People suffering from cardiovascular disease (CVD) often suffer from depression too- something that can lead to a viciou ...
JAN 17, 2020
Cardiology
JAN 17, 2020
Eating Walnuts Reduces Risk of Heart Disease
Walnuts may be more than just a tasty snack. Researchers from the University of Pennsylvania have found that they may al ...
FEB 21, 2020
Cardiology
FEB 21, 2020
Poor Sleep Increases Heart Disease Risk in Women
Researchers from Columbia University Irving Medical Center have found that women who don’t sleep well leading tend ...
APR 25, 2020
Cardiology
APR 25, 2020
Young People with COVID-19 Die from Stroke
Hospitals around the US have reported that people aged between 20 and 50 with no risk factors are dying from strokes aft ...
MAY 08, 2020
Drug Discovery & Development
MAY 08, 2020
Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People
While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidenc ...
MAY 11, 2020
Cardiology
MAY 11, 2020
Urbanization and Cardiometabolic Risk
A recent study by the Barcelona Institute for Global Health (ISGlobal) was first to analyze the possible connection betw ...
Loading Comments...